Zoetis stock has fallen over 50% in the past year due to inflation, weaker U.S. pet demand, and rising competition, prompting a cut in 2026 guidance. Despite these challenges, Zoetis maintains a solid balance sheet, a well-covered dividend with a 39% payout ratio, and ongoing share buybacks, supporting long-term shareholder value. Trading at a forward P/E of 11.5x, well below peers and historical averages, the stock offers over 60% upside potential. However, macroeconomic risks and short-term pressures lead to a cautious hold rating for now.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
